Moderna skyrockets 16% to record high after FDA clears coronavirus vaccine for phase 2 study

· *Moderna stock surged as much as 16% early Thursday after the company announced its coronavirus vaccine candidate received FDA approval for phase 2 trials.*
· *The biotech firm is preparing for a phase 3 study to begin in the early summer with the goal of marketing the drug as early as 2021, according to a Thursday...